-
Article
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
Novel and highly effective drugs for non-melanoma skin cancer (NMSC) improve patient outcomes, but their high cost strains healthcare systems. Spain’s decentralized public health system, managed by 17 autonomo...
-
Article
Access to melanoma drugs in Spain: a cross-sectional survey
The development of highly active drugs has improved the survival of melanoma patients, but elevated drug prices place a significant burden on health care systems. In Spain, the public health care system is tra...
-
Article
Open AccessSEOM-GEM clinical guidelines for cutaneous melanoma (2023)
Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with co...
-
Article
Open AccessHealth-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC...
-
Article
Open AccessBRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy
NRAS-mutated melanoma lacks a specific line of treatment. Metabolic reprogramming is considered a novel target to control cancer; however, NRAS-oncogene contribution to this cancer hallmark is mostly unknown. Her...
-
Article
Open AccessIntermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested ...
-
Article
Open AccessSTK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation
Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. STK11 (LKB1) appears to be inactivated in human cancer. However, somatic missense mutations also occur, and the ...
-
Article
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
Basal cell carcinoma (BCC) is the most frequent cancer in humans and results from constitutive activation of the Hedgehog pathway1. Several Smoothened inhibitors are used to treat Hedgehog-mediated malignancies, ...
-
Article
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR
Epigenetic inactivation of a Rab GTPase activating protein confers metastatic properties in melanoma, and it correlates with poor prognosis but better sensitivity to therapy by targeting EGFR signaling.
-
Article
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Trever Bivona and colleagues show that the Hippo pathway effector YAP promotes resistance to RAF and MEK inhibitor therapy in multiple types of BRAF-mutant tumors. The findings suggest that combined suppression o...
-
Article
The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer
Recent advances in breast cancer research have allowed deconstruction of the molecular profile of the most relevant breast cancer subtypes. This has led to an increase in treatment options, including more pers...
-
Article
HER2 and hormone receptor-positive breast cancer—blocking the right target
Chemotherapy and trastuzumab is standard therapy for HER2-positive breast cancer, although aromatase inhibitors combined with anti-HER2 therapies is an option in patients with HER2 and hormone receptor-positiv...
